Israel’s Immunity Pharma had positive results from its Phase 2a human trial with IPL344 in amyotrophic lateral sclerosis (ALS) patients. Disease progression compared to placebo slowed by some 50% over 3 years. There were other positive indications and no serious adverse events.

https://immunitypharma.com/news/64-immunity-pharma-announces-positive-top-line-results-from-phase-2a-trial-with-ipl344-in-als-patients

https://immunitypharma.com/technology